Participated · Series B · Dec 2025

KYinno focuses on providing end-to-end oncology drug discovery services and customized product development. Its core platform offers cell-based assay validation, high-throughput compound screening, antibody discovery, and phage-display technologies that help biopharma partners accelerate immuno-oncology and next-generation kinase inhibitor programs. The company positions itself as both a service provider and a co-developer, aiming to build proprietary pipelines alongside client projects. Proceeds from its latest financing will be directed toward expanding laboratory infrastructure, upgrading technological capabilities, and advancing internal project pipelines. Although detailed operating metrics such as revenue or user counts were not disclosed, the capital raise underscores investor confidence in KYinno’s business model and growth trajectory. The presence of returning shareholder Yuanhui Chuanyi suggests continued internal support and validation.

Participated · Series C · Mar 2022

Founded in 2014, SJSemi focuses on 12-inch mid-end wafer production and end-to-end wafer-level advanced packaging and testing services, including multi-die integration and chiplet solutions. The company serves smartphones, 5G, high-performance computing, data centers, automotive and other electronics markets. SJSemi has invested heavily in R&D, notably debuting a 3x reticle TSV interposer technology in May 2024 and pursuing ultra-high density 3D multi-die integration. According to Yole and CIC Insight Consulting, SJSemi saw top revenue growth among global OSATs in 2023, and ranks No.1 in mainland China for 12-inch bumping, 12-inch WLCSP market share and wafer testing/chip probing revenue. As of 2024 it is the only provider in mainland China capable of mass-producing silicon-based 2.5D packaging solutions. The company is progressing an IPO application and is expanding its one-stop multi-die integration offerings via continued investment. SJ Semiconductor (SJSemi) is a pioneer of 12-inch MEOL foundry services in China, known for high-density bumping, WLCSP and testing. It offers advanced packaging using bumping and RDL technologies, and provides silicon interposer, fan-out wafer and substrate solutions. The company serves IC customers domestically and overseas across smartphones, networking, data center, AI and automotive markets. SJSemi leverages front-end fab management and quality systems to deliver high-performance advanced packaging. Financially, the company has completed a $340M Series C+ tranche that pushes total capital raised above $1 billion and valuation close to $2 billion. Management has indicated it will remain open to additional US dollar funding and will close an RMB tranche after required ODI approvals. SJSemi is a Jiangyin, China-based MEOL foundry founded in August 2014. The company provides Middle-End-Of-Line manufacturing and testing services and develops advanced bumping and 3D Multi-Die Integration technology and solutions. Its core capabilities focus on advanced bumping and 3D multi-die integration for semiconductor packaging. SJSemi closed a $300M Series C that brings its total equity raised to $630M, strengthening its balance sheet. The company says the funding will enable it to continue growing according to its business plan and strengthen its position in advanced packaging. Backers on the round included CMBI, CICC Capital, Oriza Rivertown, Oriza Hua Capital, Walden CEL, CCB PE, CCB Trust, Growth, Country Garden Venture, HTPE, SCGC, CITIC Securities, GP Capital and others.

Participated · Series C · Sep 2021

Iaso Biotherapeutics is a clinical-stage Chinese biopharmaceutical company focused on discovering, developing, and manufacturing innovative cell therapies and antibody products. Its core platforms include a fully human antibody discovery platform (IMARS), a high-throughput CAR-T screening platform, and proprietary manufacturing processes. The company has a diversified clinical-stage pipeline of over 10 novel autologous and allogeneic CAR-T and biologics candidates, led by Equecabtagene Autoleucel (CT103A), a fully human BCMA CAR-T injection. Equecabtagene Autoleucel has received NDA acceptance from China’s NMPA for relapsed/refractory multiple myeloma and IND approval from the U.S. FDA; it also received NMPA Breakthrough Therapy Designation (Feb 2021) and FDA Orphan Drug Designation (Feb 2022). The company has an in-house CD19/CD22 dual-targeted CAR-T that holds two IND clearances for r/r B-NHL and r/r B-ALL and is in a Phase I trial for r/r B-NHL; that program received FDA ODD in Oct 2021. The recent financing is intended to support R&D across the pipeline and the commercial launch of Equecabtagene Autoleucel. IASO Biotherapeutics is a clinical-stage biopharmaceutical company focused on discovering, developing, and manufacturing novel cell therapies and biologics for oncology and autoimmune diseases. The company leverages proprietary platforms including a fully human antibody discovery platform (IMARS), a high-throughput CAR-T drug discovery platform, and proprietary manufacturing processes. IASO Bio’s pipeline includes multiple autologous and allogeneic CAR-T and biologics candidates—a diversified portfolio of eight novel pipeline products—with lead asset CT103A (anti-BCMA CAR-T) in a pivotal trial for relapsed/refractory multiple myeloma. Its fully human CD19/CD22 dual-targeted CAR-T received NMPA IND clearances in July 2021 and a fully human CD5 CAR-T has completed preclinical work and is in pre-IND stage. The company plans to use new proceeds to accelerate global development and regulatory submissions, build a broader universal allogeneic cell-therapy pipeline including products for solid tumors, expand global strategic partnerships, and advance CT103A into frontline, combination, indication-expansion, and overseas development. Iaso Biotherapeutics is a clinical-stage biotech focused on development of innovative cell therapies for cancer, including autologous and universal CAR-T products for hematological tumors and TCR-like CAR-T candidates for certain solid tumors. The company is developing more than 10 pipeline products, all based on fully human sequences, and maintains a proprietary phage display library (>2×10^11) to support fully-human antibody discovery. Iaso Bio also operates in-house plasmid, lentivirus and CAR-T production technology platforms capable of supporting IND submissions and clinical research for multiple products. In September 2019 the company received NMPA approval of a phase Ib/II IND for CT103A, an anti-BCMA CAR-T co-developed with Innovent Biologics, and several new candidates are in preclinical stages or investigator-initiated trials. The company plans to use new financing to expand its pipeline, advance regulatory applications and clinical trials in China and the United States, improve its fully-human antibody development platform, grow cooperation with international R&D institutions, and accelerate construction of commercial facilities. Iaso Bio was founded in March 2017 and is based in Nanjing, China.

Participated · Series C · Aug 2021

MediTrust is a Shanghai-based private healthcare payor founded in 2017 and led by founder and CEO Seth Zhang. It leverages proprietary integrated platforms to serve healthcare and insurance companies, delivering comprehensive healthcare products and services aimed at lowering medical costs. A core service, Care2Pay, partners with more than 50 pharmaceutical and insurance companies and over 2,000 DTP pharmacies, with national coverage in over 400 cities. Care2Pay enables millions of patients with cancer, chronic, and rare diseases to access innovative drugs more affordably; in the first half of 2021 it helped patients and families save over RMB300 million in healthcare expenditures. MediTrust also collaborates with insurers to launch municipal health insurance products in more than 40 cities, including Beijing and Shanghai, and has been instrumental in Shanghai’s Huhuibao coverage expansion.

Participated · Equity · Dec 2020

MicroTech Medical Co., Ltd. announced it raised CNY 575 million in a funding round on December 8, 2020. The capital was provided by a group of new and returning investors. The round was co-led by Tencent Holdings Ltd., IDG Capital Partners Co., Ltd., and Taikang Qianzhen Fund. Other participants included CICC Jia Cheng Investment Management, Sanzheng Health, China Everbright Limited (SEHK:165), Zhongjin Pucheng Investment, and 3H Health Investment Management. Returning investors included Qiming Weichuang Venture Capital Management (Shanghai) Company Limited, Lilly Asia Ventures, CD Capital, Shanghai Guofang FOF Equity Investment Management Co., Ltd., and Zhejiang Juren Capital Management Co., Ltd. The articles do not disclose use of proceeds, valuation, or operating metrics.